NEWS

March 1, 2021 —U.S. Commercial Launch Underway— WALTHAM — March 1, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen, in […]

FOR IMMEDIATE RELEASE February 23, 2021 STATEMENT FROM – NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org ANY WILLING PROVIDER – STILL A MAJOR ISSUE IN ONCOLOGY As we begin to navigate 2021, it is important for the oncology community to speak […]

FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50% Libtayo was superior in extending overall survival compared to chemotherapy in a pivotal trial that allowed for certain disease characteristics frequently underrepresented in advanced NSCLC trials This is the third approval for Libtayo in the U.S. […]

Written by: Joshua Nubla, PharmD, NCODA Download Here Description: The purpose of this PQI is to help provide awareness of larotrectinib and educate on management techniques. Background: Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumors that: Have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired […]

Cazenovia, NY – NCODA, Inc. is pleased to announce its collaboration with Evofem Biosciences to positively impact the quality of life for female patients undergoing treatment, those recovering from cancer, and survivors by raising awareness about the importance and availability of a new non-hormonal birth control method, Phexxi® (lactic acid, citric acid and potassium bitartrate). […]

FOR IMMEDIATE RELEASE February 8, 2021 NCODA Welcomes Five New Executive Council Members Cazenovia, NY – NCODA, Inc. is pleased to announce the addition of five new members to the Executive Council. Paul Chadwick (Florida Cancer Specialists & Research Institute), Lucio Gordan, MD (Florida Cancer Specialists & Research Institute), Benjamin Lowentritt, MD (Chesapeake Urology), Stacey […]

SAN DIEGO, Feb. 4, 2021 /PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) and NCODA (National Community Oncology Dispensing Association, Inc.), a premier educational platform for community and academic oncology practices nationwide, are launching a collaboration to positively impact the quality of life for female patients living with, fighting and recovering from cancer by raising awareness about the importance and […]

Exelixis is pleased to announce the FDA approval of its first combination therapy–CABOMETYX + OPDIVO–for the first-line treatment of patients with advanced renal cell carcinoma (aRCC).1 This new approval in aRCC is supported by clinical data from the CheckMate-9ER trial. The major efficacy outcome measure was PFS.* Additional efficacy outcome measures were OS and ORR.* […]

Daiichi Sankyo and AstraZeneca are excited to announce that ENHERTU® (fam-trastuzumab deruxtecan-nxki) is now approved for a new indication. ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate that was recently approved for use in adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based […]

Accelerated approval of DARZALEX FASPRO-based combination regimen supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher hematologic complete response rate in this rare and serious blood cell disorder January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of […]

FOR IMMEDIATE RELEASE December 23, 2020   STATEMENT FROM EXECUTIVE DIRECTOR: MICHAEL REFF Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org MOST FAVORED NATION: TEMPORARY RESTRAINING ORDER ISSUED NCODA has been in opposition of the Most Favored Nation (MFN) model for Medicare patients since it was announced late […]

FOR IMMEDIATE RELEASE December 18, 2020 STATEMENT FROM EXECUTIVE DIRECTOR: MICHAEL REFF Contact: Kevin Scorsone, NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org https://www.ncoda.org MOST FAVORED NATION MODEL: NOT THE ANSWER FOR PATIENTS NCODA is in opposition of the Most Favored Nation (MFN) model for Medicare patients that would negatively affect patient access […]